Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Recommendation of "Moderate Buy" from Analysts

Genmab A/S Sponsored ADR (NASDAQ:GMAB - Get Free Report) has earned a consensus rating of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, seven have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $37.60.

GMAB has been the subject of several recent analyst reports. Wall Street Zen downgraded Genmab A/S from a "buy" rating to a "hold" rating in a research note on Saturday, June 14th. William Blair upgraded Genmab A/S from a "market perform" rating to an "outperform" rating in a research note on Tuesday, March 11th. Sanford C. Bernstein downgraded Genmab A/S from a "market perform" rating to an "underperform" rating in a research note on Tuesday, April 1st. Truist Financial decreased their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating for the company in a research note on Tuesday, March 11th. Finally, HC Wainwright reissued a "buy" rating and set a $37.00 price objective (down previously from $50.00) on shares of Genmab A/S in a research report on Wednesday, April 9th.

Genmab A/S Price Performance

Shares of NASDAQ GMAB opened at $20.52 on Tuesday. The business's 50-day moving average price is $21.00 and its two-hundred day moving average price is $20.72. Genmab A/S has a one year low of $17.24 and a one year high of $28.56. The company has a market capitalization of $13.16 billion, a P/E ratio of 11.66, a price-to-earnings-growth ratio of 6.69 and a beta of 0.94.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $0.31 EPS for the quarter, beating analysts' consensus estimates of $0.23 by $0.08. Genmab A/S had a return on equity of 18.08% and a net margin of 35.11%. The firm had revenue of $715.00 million for the quarter, compared to the consensus estimate of $5.17 billion. On average, equities analysts anticipate that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently added to or reduced their stakes in GMAB. Orbis Allan Gray Ltd raised its holdings in shares of Genmab A/S by 102.8% in the 1st quarter. Orbis Allan Gray Ltd now owns 5,710,741 shares of the company's stock worth $111,816,000 after buying an additional 2,895,179 shares in the last quarter. Deep Track Capital LP bought a new position in Genmab A/S in the 4th quarter valued at $41,740,000. Renaissance Technologies LLC boosted its position in Genmab A/S by 7.8% in the 4th quarter. Renaissance Technologies LLC now owns 1,926,150 shares of the company's stock valued at $40,199,000 after buying an additional 139,722 shares during the last quarter. Brandywine Global Investment Management LLC lifted its stake in shares of Genmab A/S by 6.0% in the 1st quarter. Brandywine Global Investment Management LLC now owns 1,717,397 shares of the company's stock valued at $33,627,000 after purchasing an additional 97,633 shares during the period. Finally, Two Sigma Investments LP lifted its stake in shares of Genmab A/S by 122.2% in the 4th quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock valued at $35,612,000 after purchasing an additional 938,455 shares during the period. Institutional investors and hedge funds own 7.07% of the company's stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.